1. P557 Sustained remission in inflammatory bowel disease patients after discontinuing infliximab; the ongoing reluctance to stop biologics. (25th January 2019) Authors: Ryan, T; Coffey, L; Mullen, A; Leyden, J; MacMathuna, P Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S392 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 5 Outcomes following ANTI-TNF discontinuation and the risk of relapse in inflammatory bowel disease; a single centre experience. (5th April 2017) Authors: Coffey, L; Mullen, A; Leyden, J; MacMathuna, P Journal: Gut Issue: Volume 66(2017)Supplement 1 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Obesity association with antidiabetic drugs' prescription among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. (1st April 2022) Authors: Mahmoud, F; Mullen, A; Yasin, H; Abutheraa, N; Kurdi, A Journal: International journal of pharmacy practice Issue: Volume 30(2022)Supplement 1 Page Start: i11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dreaming, fenfluramine, and vitamin C. Issue 6053 (8th January 1977) Authors: Mullen, A; Wilson, C W; Wilson, B P Journal: BMJ Issue: Volume 1:Issue 6053(1977) Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗